Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Ren et al., 2025
Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap with Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap with Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap With Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Ren et al., 2024
Rosnilimab, a PD-1 Agonist Antibody in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis
Parmley et al., 2024
Imsidolimab, an IL-36 Receptor Antagonist, Was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients With Generalized Pustular Psoriasis Results From the Phase 3 Trials, GEMINI-1 and GEMINI-2
Reich et al., 2024
Atopic Dermatitis is Characterized by Enrichment in a BTLA Transcriptomic Signature
Ren et al., 2024
ANB032, a BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Muench et al., 2024
ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Soroosh et al., 2024
ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease
Hare et al., 2024
Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling
Parmley et al., 2024
ANB032, a BTLA (B and T Cell Lymphocyte Attenuator) Checkpoint Receptor Agonist, Modulates Dendritic Cell Maturation and Function
Soroosh et al., 2024
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2024